VANCOUVER, British Columbia - Optimi Health Corp. (NASDAQ:OPTH) (CSE:OPTI) (FSE:8BN0) closed its underwritten public offering today in connection with the uplisting of its common shares to the Nasdaq Capital Market.
The pharmaceutical company issued 2,400,000 common shares at $6.25 per share, generating gross proceeds of $15 million before deducting underwriting discounts and offering expenses.
"This financing provides significant strength to our balance sheet and represents the necessary working capital for the growth of our business," said Dane Stevens, CEO of Optimi.
The company faces financial headwinds, with a market cap of $1.9 million and a "WEAK" financial health score. The stock has fallen 69% year-to-date.
Common shares began trading on the Nasdaq Capital Market on Tuesday under the symbol "OPTH." Shares continue to trade on the Canadian Securities Exchange under "OPTI."
Joseph Gunnar & Co., LLC served as sole book-running manager. The company granted the underwriter 96,000 non-transferable common share purchase warrants.
A registration statement on Form F-1 was filed with the SEC and declared effective on May 19, 2026.
Optimi Health is a commercial-stage pharmaceutical company focused on manufacturing and distributing psychedelic drug products.
